These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. L-Carnitine supplementation decreases DNA damage in treated MSUD patients. Mescka CP; Guerreiro G; Hammerschmidt T; Faverzani J; de Moura Coelho D; Mandredini V; Wayhs CA; Wajner M; Dutra-Filho CS; Vargas CR Mutat Res; 2015 May; 775():43-7. PubMed ID: 25867118 [TBL] [Abstract][Full Text] [Related]
3. Protein and lipid damage in maple syrup urine disease patients: l-carnitine effect. Mescka CP; Wayhs CA; Vanzin CS; Biancini GB; Guerreiro G; Manfredini V; Souza C; Wajner M; Dutra-Filho CS; Vargas CR Int J Dev Neurosci; 2013 Feb; 31(1):21-4. PubMed ID: 23137711 [TBL] [Abstract][Full Text] [Related]
4. Prevention of DNA damage by L-carnitine induced by metabolites accumulated in maple syrup urine disease in human peripheral leukocytes in vitro. Mescka CP; Wayhs CA; Guerreiro G; Manfredini V; Dutra-Filho CS; Vargas CR Gene; 2014 Sep; 548(2):294-8. PubMed ID: 25046137 [TBL] [Abstract][Full Text] [Related]
5. L-carnitine Prevents Oxidative Stress in the Brains of Rats Subjected to a Chemically Induced Chronic Model of MSUD. Mescka CP; Rosa AP; Schirmbeck G; da Rosa TH; Catarino F; de Souza LO; Guerreiro G; Sitta A; Vargas CR; Dutra-Filho CS Mol Neurobiol; 2016 Nov; 53(9):6007-6017. PubMed ID: 26526843 [TBL] [Abstract][Full Text] [Related]
6. Urinary biomarkers of oxidative damage in Maple syrup urine disease: the L-carnitine role. Guerreiro G; Mescka CP; Sitta A; Donida B; Marchetti D; Hammerschmidt T; Faverzani J; Coelho Dde M; Wajner M; Dutra-Filho CS; Vargas CR Int J Dev Neurosci; 2015 May; 42():10-4. PubMed ID: 25680940 [TBL] [Abstract][Full Text] [Related]
7. DNA damage induced by alloisoleucine and other metabolites in maple syrup urine disease and protective effect of l-carnitine. Hauschild TC; Guerreiro G; Mescka CP; Coelho DM; Steffens L; Moura DJ; Manfredini V; Vargas CR Toxicol In Vitro; 2019 Jun; 57():194-202. PubMed ID: 30853490 [TBL] [Abstract][Full Text] [Related]
8. In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease. Mescka C; Moraes T; Rosa A; Mazzola P; Piccoli B; Jacques C; Dalazen G; Coelho J; Cortes M; Terra M; Regla Vargas C; Dutra-Filho CS Metab Brain Dis; 2011 Mar; 26(1):21-8. PubMed ID: 21380499 [TBL] [Abstract][Full Text] [Related]
9. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Barschak AG; Sitta A; Deon M; Barden AT; Dutra-Filho CS; Wajner M; Vargas CR Metab Brain Dis; 2008 Mar; 23(1):71-80. PubMed ID: 18026828 [TBL] [Abstract][Full Text] [Related]
10. Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Barschak AG; Sitta A; Deon M; de Oliveira MH; Haeser A; Dutra-Filho CS; Wajner M; Vargas CR Metab Brain Dis; 2006 Dec; 21(4):279-86. PubMed ID: 17091400 [TBL] [Abstract][Full Text] [Related]
11. Investigation of L - Carnitine Concentrations in Treated Patients with Maple Syrup Urine Disease. Kumru B; Oztürk Hismi B J Pediatr Genet; 2019 Sep; 8(3):133-136. PubMed ID: 31406618 [TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids. Amaral AU; Wajner M Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033 [TBL] [Abstract][Full Text] [Related]
13. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Ribas GS; Vargas CR; Wajner M Gene; 2014 Jan; 533(2):469-76. PubMed ID: 24148561 [TBL] [Abstract][Full Text] [Related]
14. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. Deon M; Guerreiro G; Girardi J; Ribas G; Vargas CR Int J Dev Neurosci; 2023 Oct; 83(6):489-504. PubMed ID: 37340513 [TBL] [Abstract][Full Text] [Related]
15. Melatonin ameliorates oxidative stress and DNA damage of rats subjected to a chemically induced chronic model of Maple Syrup Urine Disease. Wessler LB; Ise K; Lemos IC; Rezende VL; Duarte MB; Damiani AP; de Oliveira J; de Andrade VM; Streck EL Metab Brain Dis; 2020 Aug; 35(6):905-914. PubMed ID: 32297169 [TBL] [Abstract][Full Text] [Related]
16. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine. Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005 [TBL] [Abstract][Full Text] [Related]
17. Preliminary results of PBA-loaded nanoparticles development and the effect on oxidative stress and neuroinflammation in rats submitted to a chemically induced chronic model of MSUD. Mescka CP; de Moura Coelho D; Sitta A; Catarino F; Donida B; Rosa AP; Gonzalez EA; Pinheiro CV; Poletto F; Baldo G; Dutra-Filho CS; Vargas CR Metab Brain Dis; 2021 Jun; 36(5):1015-1027. PubMed ID: 33620579 [TBL] [Abstract][Full Text] [Related]
18. Acute effects of intracerebroventricular administration of α-ketoisocaproic acid in young rats on inflammatory parameters. Rabelo F; Lemos IDS; Dal Toé CP; Casagrande DD; Freitas MLS; Quadra MR; Lima IR; Generoso JS; Michels M; Silveira PCL; Pizzol FD; Streck EL Metab Brain Dis; 2023 Jun; 38(5):1573-1579. PubMed ID: 36897514 [TBL] [Abstract][Full Text] [Related]
19. Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease. Schadewaldt P; Hammen HW; Ott AC; Wendel U J Inherit Metab Dis; 1999 Aug; 22(6):706-22. PubMed ID: 10472531 [TBL] [Abstract][Full Text] [Related]
20. Memantine Improves Memory and Neurochemical Damage in a Model of Maple Syrup Urine Disease. Lemos IDS; Torres CA; Alano CG; Matiola RT; de Figueiredo Seldenreich R; Padilha APZ; De Pieri E; Effting PS; Machado-De-Ávila RA; Réus GZ; Leipnitz G; Streck EL Neurochem Res; 2024 Mar; 49(3):758-770. PubMed ID: 38104040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]